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Introduction
Patients with ileal resection or extensive jejunal resec-
tion resulting in malabsorption are likely to develop
renal hyperoxaluria [1-3]. Deficiencies due to malab-
sorption can be avoided if supplementation therapy is
instituted as early as possible, but in patients with
extensive bowel resection steatorrhoea cannot be cor-
rected completely. Hyperoxaluria due to hyperabsorp-
tion of oxalic acid or its precursors is a well-established
phenomenon, leading to renal complications such as
recurrent urolithiasis, oxalate nephropathy, and ulti-
mately end-stage renal failure [4-6]. In this report we
describe a female patient with a severe malabsorption
syndrome and hyperoxaluria after extensive small-
bowel resection. Five years after the initial operation
the patient suffered from recurrent stone formation
and occasional urinary tract infections. The renal
function deteriorated continuously and 25 years after
the small-bowel resection the patient was in severe
uraemia. Six months after starting maintenance haemo-
dialysis the patient received a cadaveric kidney trans-
plant. Despite persisting hyperoxaluria during the first
5 years after transplantation the transplant has con-
tinued to function normally over a period of 7 years
with normalization of urinary oxalate excretion and
no further stone formation occurred. To our knowledge
this is the first reported case of a long-term successful
kidney transplantation in a patient with a short-bowel
syndrome and enteric hyperoxaluria.
Case report
In 1958 at the age of 33 years this female patient
underwent surgery for myoma and appendectomy
without appendicitis. Three years later, in 1961, an
extensive resection of necrotic small bowel was neces-
sary because of unrecognized bowel obstruction.
Approximately 90 cm of small bowel and most of
the large bowel remained. Barium passage from
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stomach to caecum was found to take only 15 min.
Consequently the patient developed a severe global
malabsorption syndrome and a weight loss of 20 kg in
less than 2 years. When the patient was first seen by
us she weighed 42 kg, had a height of 162 cm, and
suffered from hypocalcaemic tetany, hypokalaemia,
and hypomagnesaemia.
The following laboratory results were obtained
(with normal values in brackets): Faecal fat 50 g/24 h
(<7g/24h), faecal nitrogen 4.7 g/day (<2g/day),
xylose absorption 15% (20-35%), vitamin B12 absorp-
tion 0.08% (>4%), lactose absorption was highly
abnormal, with severe diarrhoea. Blood serum
values: albumin 22 g/1 (>36g/l), calcium 1.8mmol/l
(>2.2 mmol/1), potassium 3.2mmol/l (>3.7mmol/l)
and magnesium 0.6 mmol/1 (>0.8 mmol/1). Serum cre-
atinine was at the upper limit of normal with 80 umol/1.
The patient received dietary counselling with the intro-
duction of a low-fat diet with the addition of medium-
chain triglycerides, vitamin supplementation, and oral
calcium 1-2 g/day. On this regime the patient gained
10 kg in weight, but suffered persistently from an
abnormal frequency and consistency of bowel move-
ments despite different drug trials.
Five years after the small-bowel resection the patient
passed a first kidney stone. Starting in 1973 the patient
suffered from recurrent stone formation on both sides
with or without obstruction or infection and Gram-
negative septicaemia. At least six times she underwent
operations to remove renal calculi. At one time she
passed 20 small renal stones within 1 month. The
chemical analyses of the stones always revealed a
calcium oxalate composition. Urinary excretion of
oxalic acid was regularly highly abnormal, above
500 umol/day. Dietary restriction of oxalic acid or
various drug trials had no permanent effect on oxalate
excretion (Figure 1); the normal values for oxalate
excretion in 1977 and 1978 were obtained during
hospitalization of the patient. Figure 2 illustrates the
progressive deterioration of the kidney function. In
1986 the patient became obliguric, probably following
ingestion of a small dose of indomethacin, and
developed uraemia, with a serum creatinine of
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Fig. 1. Renal oxalate excretion (normal value <500 umol/day).
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Fig. 2. Plasma creatinine and creatinine clearance before and after kidney transplantation in 1987.
1300umol/l and acidosis with a pH of 7.06. No
obstruction was seen on ultrasound, but both kidneys
were small. Consequently the patient was treated with
haemodialysis. Bleeding from the gastrointestinal tract
and a decreased left ventricular ejection fraction prob-
ably due to oxalate cardiomyopathy were additional
severe complications.
Six months later, in February 1987, a cadaveric
kidney transplant was performed. Initially the patient
was oliguric and a transplant biopsy on day 9 showed
ischaemic damage as well as oxalate crystal deposition
in the proximal tubular lumina. Despite oxalate crystal
deposition, the kidney resumed function on day 12,
when daily haemodialysis was instituted for another 5
days. Thereafter the renal course was uneventful. There
was never a sign of rejection despite a HLA-mismatch
of five antigens out of a total of six. Seven years after
transplantation the plasma creatinine is 70 umol/1 and
the creatinine clearance between 60 and 70 ml/min.
(Figure 2).
Before transplantation the patient had been tested
for her enteral absorption of cyclosporin and prednis-
one. While prednisone was absorbed normally, whole-
blood cyclosporin levels varied between undetectable
and barely immunosuppressive concentrations, after
oral administration of both twice 100 mg per day of
cyclosporin in olive oil as well as 100 mg or 200 mg
twice per day dissolved in medium-chain triglycerides.
Initial immunosuppression therefore consisted of intra-
venous cyclosporin 100-200 mg/day for the first 30
days combined with oral azathioprine 100 mg/day and
prednisone 20 mg/day. After discontinuing cyclospo-
rin, prednisone was increased to 40 mg/day for 10 days
followed by tapering to 10 mg/day over the next 6
months. For the last 6 years the patient has been
taking 7.5 mg prednisone and 150 mg azathioprine
daily. Complications of immunosuppressive ther-
apy included a localized pulmonary lesion with
Cryptococcus neoformans, requiring surgical resection
in 1989, and recurrent small skin tumours on the hands
and the face.
Regarding oxalate hyperabsorption the patient's
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posttransplant course has been remarkably uneventful.
Attempts to reduce oxaluria with dietary restrictions
to levels below the upper range of normal
(0.5 mmol/day) were only partially successful. During
the first 5 years after transplantation the majority of
urinary analyses showed oxalate excretion rates
between 0.6 and 0.8 mmol/day with only occasional
values below 0.5 mmol/day. The decrease of oxalate
excretion rates to normal values with only occasional
results slightly above normal during years 6 and 7 after
transplantation is difficult to explain. Oral calcium
supplementation was increased to the point where
urinary calcium excretion ranged between 3 and
5 mmol/day. Magnesium was supplemented at a dose
of 400 mg/day. A trial with organic marine hydrocol-
loid charged with calcium, although effective regarding
control of oxaluria, had to be abandoned because of
abdominal distension and constipation. Despite per-
sisting hyperoxaluria during the first few years after
transplantation, the patient was rather fortunate not
to form a single kidney stone after transplantation.
Despite persisting gastrointestinal problems with
abdominal distension, fullness, and occasional cramp-
ing pains when constipated, this patient has resumed
a fully active life as housewife, travelling around the
world and enjoying extensive and strenuous walks in
the mountains.
Comments
This is the first report of a long-term survival of a
cadaveric renal transplant over a period of 6 years
without renal complications in a patient with enteric
hyperoxaluria. In the literature we found only one
other similar case-report [7]. The patient mentioned in
that report developed end-stage renal failure due to
renal oxalosis 9 years after extensive bowel resection.
Because of difficulties with dialysis procedures he
underwent successful renal transplantation with good
renal function. The follow-up covered only 10 months
and it is not known whether complications developed
later in the course. The patient of the present report
had a course of 25 years before developing end-stage
renal insufficiency. After the transplantation persistent
hyperoxaluria with a few exceptions was observed
despite various modifications of diet and drugs. No
new stone formation or signs of oxalate nephropathy
occurred in the graft. The kidney function has remained
normal, as reflected by serum creatinine levels below
80 umol/1. Kidney biopsy was not performed to estab-
lish potential interstitial oxalate deposits. During the
last 2 years urinary oxalate excretion was mostly within
the normal range and the risk of recurrence of oxalate
lithiasis or oxalate nephropathy is therefore reduced.
Despite this uneventful course in our patient we think
that the recurrence of oxalosis or stone formation in a
renal transplant has to be watched closely.
According to our experience enteric hyperoxaluria
should not be a contraindication for renal transplanta-
tion [5,6]. There are several reports of patients with
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primary oxalosis and kidney transplantation and good
renal function when certain conditions are observed
[8-10]. We believe that in secondary hyperoxaluria
kidney transplantation should also be considered for
patients with end-stage kidney disease in preference to
maintenance dialysis. Enteric hyperoxaluria is caused
by intestinal hyperabsorption of exogenous oxalic acid
and correlates well to the degree of steatorrhoea [11].
The reduction of dietary intake of oxalic acid necessary
to lower oxaluria into the normal range is nearly
impossible to achieve outside the hospital, as others
have also observed [12,13]. Dietary counseling is
difficult because of great differences in the analytical
methods regarding content of oxalic acid in various
foods. It is important to reduce the fat content in the
diet with the addition of medium-chain triglycerides
and to supply oral calcium and magnesium salts in
large amounts. Recommended are also oral application
of citrate, resin exchange, and aluminium hydroxide
[14]. As in all patients with kidney stones a large urine
volume to avoid a supersaturated urine is of primary
importance.
Good results were recently reported with an
organic marine hydrocolloid charged with calcium
(Ox-absorb), a potent binding substance for oxalate
[15]. Because of gastrointestinal side-effects we were
not able to treat our patient over a longer period in
this way.
Another problem in a patient with global malabsorp-
tion is the correct dosage of immunosuppressive drugs.
As the absorption and bioavailability of oral cyclospo-
rin in a malabsorption syndrome is unpredictable,
cyclosporin has to be administered intravenously with
careful monitoring of serum concentrations [7]. In
order to achieve immunosuppression with oral medica-
tion our patient was put on prednisone and azathio-
prine because cyclosporin administered orally was
poorly absorbed. With a small dosage of 7.5 mg pred-
nisone and 150 mg azathioprine the renal function is
normal and no sign of rejection has occurred over the
years. In the early phase of transplantation oxalate
deposition in the new kidney has to be prevented.
Therefore intensive haemodialysis is mandatory,
should oliguria occur. In this way serum oxalate levels
can be lowered and damage to the kidney transplant
avoided. More extensive experience with transplanta-
tion has been reported in patients with primary oxalosis
[9,10]. Good results have been achieved when the
patients had a period of intensive dialyses before
transplantation. In order to avoid further oxalate
accumulation, forced diuresis after transplantation and
early haemodialysis is recommended, whenever the
cadaver kidney shows a reduced function. We think
that the same procedure can be applied for patients
with secondary hyperoxaluria. Our good experience
with this patient should encourage others to consider
kidney transplantation in patients with end-stage renal
failure due to enteric hyperoxaluria.
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